LOXL2 and neoplasm: FACS analysis of tumor tissues at the treatment endpoints showed that the combination of PD-L1 and LOXL2 inhibition significantly increased total CD8+ TILs and decreased exhausted CD8+ T cell subpopulations (Fig. 3c).